KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) EBT Margin (2016 - 2025)

BeOne Medicines (ONC) has disclosed EBT Margin for 11 consecutive years, with 16.23% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 2380.0% to 16.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 9.56%, a 2355.0% increase, with the full-year FY2025 number at 8.6%, up 2259.0% from a year prior.
  • EBT Margin was 16.23% for Q4 2025 at BeOne Medicines, up from 10.42% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 29.35% in Q3 2023 to a low of 320.4% in Q2 2021.
  • A 5-year average of 77.37% and a median of 43.84% in 2023 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: skyrocketed 70824bps in 2021, then tumbled -14759bps in 2022.
  • BeOne Medicines' EBT Margin stood at 283.22% in 2021, then skyrocketed by 60bps to 113.38% in 2022, then skyrocketed by 51bps to 55.29% in 2023, then skyrocketed by 86bps to 7.57% in 2024, then skyrocketed by 314bps to 16.23% in 2025.
  • Per Business Quant, the three most recent readings for ONC's EBT Margin are 16.23% (Q4 2025), 10.42% (Q3 2025), and 7.57% (Q2 2025).